Is lisinopril an ace inhibitor
Searched over 200M research papers
Summary
10 papers analyzed
These studies suggest lisinopril is an ACE inhibitor.
Consensus Meter
9 papers analyzed
Yes - 100%
Possibly - 0%
No - 0%
Research summarized with Copilot
Beta20 papers analyzed
Lisinopril as an ACE Inhibitor: A Comprehensive Overview
Introduction to ACE Inhibitors
Angiotensin-converting enzyme (ACE) inhibitors are a class of medications widely used in the treatment of hypertension, heart failure, myocardial infarction, and diabetic nephropathy. These drugs function by inhibiting the enzyme ACE, which plays a crucial role in the renin-angiotensin-aldosterone system (RAAS) that regulates blood pressure and fluid balance.
Lisinopril: An Effective ACE Inhibitor
Mechanism of Action
Lisinopril is a potent ACE inhibitor that prevents the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. By inhibiting this conversion, lisinopril helps to lower blood pressure and reduce the workload on the heart . The drug binds to the ACE enzyme, blocking its activity and thereby reducing the levels of angiotensin II in the body.
Clinical Efficacy in Heart Failure
Lisinopril has been extensively studied for its effects on heart failure. The ATLAS study demonstrated that high doses of lisinopril significantly reduced the risk of death or hospitalization in patients with chronic heart failure compared to low doses. This suggests that higher doses of lisinopril may offer more substantial benefits in managing heart failure.
Impact on Renal Disease
In patients with insulin-dependent diabetes mellitus (IDDM), lisinopril has shown a significant beneficial effect on renal disease progression. The EURODIAB Controlled Trial found that lisinopril significantly reduced the albumin excretion rate (AER) in patients with the II genotype of the ACE gene, indicating its potential in slowing the progression of renal disease in specific genetic populations.
Benefits in Acute Myocardial Infarction
Lisinopril has also been shown to reduce mortality in diabetic patients with acute myocardial infarction (MI). The GISSI-3 study revealed that early treatment with lisinopril significantly decreased 6-week mortality rates in diabetic patients, supporting its use in acute MI management.
Pharmacokinetics and Bioavailability
Lisinopril is known for its long-acting properties, allowing for once-daily dosing. This is in contrast to other ACE inhibitors like captopril, which require multiple doses per day. Studies have shown that lisinopril maintains stable potassium, urea, and creatinine levels, indicating good tolerability and a stable pharmacokinetic profile.
Structural Insights and Domain Selectivity
The crystal structure of the human ACE-lisinopril complex has provided valuable insights into the drug's binding specificity. Lisinopril binds to both the N- and C-domains of the ACE enzyme, but modifications like lisinopril-tryptophan (LisW-S) have been developed to selectively inhibit the C-domain. This selectivity could potentially reduce side effects and improve therapeutic outcomes .
Conclusion
Lisinopril is a well-established ACE inhibitor with proven efficacy in treating hypertension, heart failure, acute myocardial infarction, and renal disease. Its long-acting nature and ability to significantly impact morbidity and mortality make it a valuable drug in cardiovascular and renal medicine. The ongoing research into domain-selective inhibitors like LisW-S may further enhance its therapeutic profile, offering more targeted and effective treatment options.
Sources and full results
Most relevant research papers on this topic
